Quality of life research: adding an important dimension to the evaluation of therapeutic outcomes

Hamilton, Ann S.

doi:10.3109/10428194.2010.551161

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The demands of comorbid conditions, psychological distress, and general disease burden must be endured and balanced against treatment efficacy [8,9,[16][17][18][19][20][21][22]. Recent work has examined the longitudinal effects of 2 Lymphoma disease and treatment, including quality-of-life considerations and the cost-effectiveness of treatment [22][23][24][25][26][27][28][29][30][31][32][33]. NHL treatment has often been evaluated without a specific focus on the self-reported concerns and symptoms of patients.…”

Section: Introductionmentioning

confidence: 99%

The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)

et al. 2013

View full text Add to dashboard Cite

Background. The individual concerns of non-Hodgkin’s lymphoma (NHL) patients require identification and assessment during clinical research proposing to measure patients’ outcomes. The FACT-Lym was developed as part of the FACIT measurement system to address health-related quality-of-life (HRQL) issues for NHL patients.Patients and Methods. Items for the FACT lymphoma subscale (LymS) were generated from healthcare provider interviews, published literature, and content validity patient interviews. The FACT-Lym was validated on a sample of 84 NHL patients, with additional measures at baseline (T1), 3–7 days (T2), and 8–12 weeks (T3).Results. Item correlations, expert relevance ratings, and patient input on content shortened the initial 22-item LymS to 15 items. The validation sample included 56% female, 76.2% white, 60% indolent disease, and 85% receiving treatment. Internal consistency coefficients for the 15-item LymS (.79, .85, and .84 T1–T3) and test-retest stability (.84) indicated good reliability. Correlations between LymS and SF-36 physical (r=.62) and mental (r=.48) summary scores reflect concurrent validity. Responsiveness to ECOG performance status and treatment status exceeded established FACT subscale scores. The FACT-LymS differentiated patients’ retrospective ratings of change in each of the three groups (better; unchanged; worse),P<0.001.Conclusions. These results support the validity of the FACT-Lym and suggest it will be a useful targeted endpoint in NHL clinical research.

show abstract